Biotech CEO: Bayh-Dole 'fix' won't lower drug prices
May 17, 2024 at 05:10 AM EDT
A proposal to amend Bayh-Dole won’t, in fact, have the intended impact of reducing drug prices, writes John Glasspool, CEO of Anthos Therapeutics Inc. in Cambridge.
